US 8461203

I'll search for authoritative information on US patent 8461203, including USPTO records and any CAFC litigation.

Let me search specifically for 2026 CAFC dockets and any recent litigation involving this patent.

Let me pin down the actual granted claims of the '203 patent (the user's provided text was truncated before the claims).

US Patent 8,461,203 — Analyst Summary

Important framing note: I searched for the specific identifier 8461203 / 8,461,203 and did not substitute any look‑alike numbers (e.g., 8,461,197; 8,461,216; 8,462,409). Where sources disagree, I flag it. I could not confirm any 2026 Court of Appeals for the Federal Circuit (CAFC) docket naming this patent — see the Litigation section.

Bibliographic data

Source: https://patents.google.com/patent/[US8461203B2](/patent/US8461203B2)/en ; https://www.drugpatentwatch.com/p/patent-exob/8461203

Continuity (as recited on the face of the patent)

13/182,324 is a continuation of 12/913,644 (filed Oct. 27, 2010), a continuation of 11/777,877 (filed Jul. 13, 2007; issued as 7,851,506), a divisional of 10/841,709 (filed May 7, 2004; issued as 7,262,219), a divisional of 10/194,021 (filed Jul. 11, 2002; issued as 6,780,889), a divisional of 09/470,570 (filed Dec. 22, 1999; issued as 6,472,431), which claims priority to provisional 60/113,745 (Dec. 23, 1998).

⚠️ Identifier caution: The specifications are nearly identical across this family, and several sibling applications were published with the same title (e.g., 20130143965, from application 13/685,561, filed Nov. 26, 2012). Do not conflate the claims of 13/685,561 (which begin "1‑9. (canceled); 10. A pharmaceutical composition…") with the claims of the '203 patent (application 13/182,324).

Abstract (verbatim, as published)

"Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gamma-hydroxybutyrate that are also resistant to the conversion into GBL. Disclosed are methods to treat sleep disorders, including narcolepsy, with these stable formulations of GHB. The present invention also provides methods to treat alcohol and opiate withdrawal, reduced levels of growth hormone, increased intracranial pressure, and physical pain in a patient."

Independent claims — plain language

The '203 patent is directed to methods of rendering an aqueous GHB medium self‑preserving (i.e., resistant to microbial growth) without a preservative. There is no independent composition claim; the composition claims of the family sit in siblings such as 6,780,889 and 7,262,219, which recite "500 mg/ml sodium gamma‑hydroxybutyrate … malic acid … pH of about 7.5 … free of preservatives."

(1) Claim 1 — A method of rendering an aqueous medium resistant to microbial growth, comprising (a) admixing a salt of gamma‑hydroxybutyrate with the aqueous medium; (b) adjusting the GHB salt concentration to a final concentration of about 310 to about 750 mg/ml; and (c) adjusting the pH to about 6 to about 9; such that the medium is chemically stable and resistant to microbial growth, "wherein the medium would not need to contain a preservative."

(2) Claim 9 — A method of rendering an aqueous medium comprising a salt of GHB resistant to microbial growth, comprising adjusting the concentration to about 310–750 mg/ml and the pH to about 6–9, so the medium is chemically stable and [resistant to microbial growth] (same functional endpoint, phrased from the medium side).

(3) Claim 10 — Same as claim 1 but reciting "contacting a salt of gamma hydroxybutyrate with the aqueous medium," and ending "wherein the medium does not contain a preservative."

Representative dependents: claim 2 (salt is sodium GHB); claim 3 (pH‑adjusting agent is an organic acid); claim 5 (about 450–600 mg/ml); claim 6 (about 500 mg/ml); claims 7–8 (components admixed sequentially/simultaneously); claim 16 ("medium does not contain a preservative").

Sources: https://www.drugpatentwatch.com/p/patent-exob/8461203 ; https://ptacts.uspto.gov/ptacts/public-informations/petitions/[1459711](/patent/1459711)/download-documents?artifactId=SuU1kui1xQlxY2eMXqnGf4dxsmr3N82Oy7p6M5iMb45oec_J6YmOzvQ

Technical point that drives the claims: the inventors found GHB concentration itself confers preservative‑like resistance above ~150 mg/ml, and that GBL (gamma‑butyrolactone) degradation is pH‑dependent — GBL begins forming at pH ≈6 or below. So the claimed window (310–750 mg/ml; pH 6–9) is a compromise between antimicrobial effectiveness (which degrades at high pH) and chemical stability (which degrades at low pH).

Claim construction / litigation on the '203 patent (D.N.J.)

The '203 patent is part of what the court called the "'431 patent family." In Jazz Pharmaceuticals, Inc. v. Roxane Laboratories, Inc., the court construed:

• "pH‑adjusting agent" = "compositions that achieve a desired pH" (Civ. No. 10‑6108, D.I. 151).
• "preservative" = "a substance or substances added in addition to the gamma‑hydroxybutyrate salt to inhibit chemical change or microbial action."
• "admix" / "contacting" — no construction necessary; the court rejected Roxane's attempt to require a pre‑formed salt added from outside the solution (Civ. No. 2:15‑cv‑01360, D.I. 84, Nov. 4, 2016).

Google Patents lists related N.J. dockets: 2:13‑cv‑05450, 2:13‑cv‑07884, 2:14‑cv‑04467, 2:14‑cv‑07757, 2:15‑cv‑01360, 2:15‑cv‑05619, 2:15‑cv‑06548, 2:17‑cv‑05487, and E.D.N.Y. 2:17‑cv‑04439.

CAFC 2026 dockets — explicit uncertainty statement

I found no 2026 CAFC docket, opinion, or order involving US 8,461,203. This is consistent with the patent's status: Google Patents records it as Expired – Fee Related with anticipated expiration 2019‑12‑22 (20 years from the Dec. 22, 1999 filing of 09/470,570). A patent that expired in 2019 would not normally be the subject of a live 2026 appeal.

The Jazz sodium‑oxybate Federal Circuit activity I did locate concerns other patents:

• Jazz Pharmaceuticals, Inc. v. Avadel CNS Pharmaceuticals, LLC, Nos. 2024‑2274/‑2277/‑2278 (Fed. Cir., decided May 6, 2025) — reversed‑in‑part, vacated‑in‑part, remanded; concerned the injunction and U.S. Patent No. 8,772,306‑family/'782 issues and §271(e) safe harbor — not the '203 patent.
• 2026 appellate news (e.g., Gibson Dunn's March 2026 Federal Circuit Update, dated Apr. 23, 2026) does not mention 8,461,203.

I cannot access PACER or the CAFC docket system directly in this session, so I cannot rule out a non‑indexed 2026 filing with certainty. If a 2026 docket exists, it is not reflected in any searchable source I could reach, and given the 2019 expiration I would treat such a report with skepticism unless independently verifiable.

Confidence and caveats

• High confidence: title, inventors, application number, filing/issue dates, priority chain, assignee, abstract, claim 1/9/10 text.
• Medium confidence: the exact anticipated expiration date (Google Patents labels it an assumption; a PTA adjustment could shift it).
• Low confidence / unverified: the specific "Jazz Pharmaceuticals Inc" current‑assignee line is Google's automated listing; the underlying assignment records show many transfers (Orphan Medical → JPI Commercial → Jazz), plus security interests (Barclays 2012, Bank of America 2015, U.S. Bank 2021) that are not ownership changes.
• Not found: any 2026 CAFC docket for this patent.

I'll research litigation involving US patent 8461203. Let me start with several targeted searches.

Let me search the specific litigation case numbers listed on the patent's page and related records.

Litigation Involving U.S. Patent No. 8,461,203

Bottom line: U.S. Patent No. 8,461,203 ("the '203 patent"), titled "Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy," was asserted as part of the Hatch‑Waxman (ANDA) patent litigation campaign over Jazz Pharmaceuticals' Xyrem® (sodium oxybate) product. The '203 patent is a member of the "'431 patent family" (described in the record as covering "composition or chemical/stability or methods of dosing patents regarding sodium gamma‑hydroxybutyrate"), stemming from U.S. Patent No. 6,472,431.

Below is what I could confirm with specific documentary evidence, followed by family‑level litigation and important caveats.

1. Directly confirmed case asserting the '203 patent

Jazz Pharmaceuticals, Inc. v. Ranbaxy Laboratories Limited and Ranbaxy Inc.

Evidence the '203 patent was at issue: The Ranbaxy complaint expressly lists the patents‑in‑suit, including "8,461,203 (the '203 patent)," alongside U.S. Pat. Nos. 6,472,431; 6,780,889; 7,262,219; 7,851,506; 8,263,650; 8,324,275; 7,668,730; 7,765,106; 7,765,107; 7,895,059; 8,457,988; 8,589,182; and 8,731,963. The suit arose from Ranbaxy's ANDA No. 203351 for a generic 500 mg/mL sodium oxybate oral solution referencing Xyrem®.

• Source (complaint text, "United States Patent Nos. 6,472,431 … 8,461,203 (the '203 patent)…"): courtlistener.com/docket/4311738 and the Scribd posting of the Complaint in 2:14‑cv‑04467.
• Source (docket/consolidation order): courtlistener.com/docket/4311738 (entry 42, Apr. 21, 2015 consolidation into 13‑391).
• Source (FJC IDB data): courtlistener.com/docket/4311738/idb/.

2. Family‑level litigation (patent‑family, not patent‑number‑specific)

Google Patents flags U.S. 8,461,203 as "Family has litigation" and lists the following related cases. Because these are reported at the family level, I could not independently confirm in the results I retrieved that the '203 patent itself was asserted in each one — treat these as associated Xyrem/oxybate‑family cases rather than verified '203 assertions:

Consolidated proceeding: Many of the New Jersey ANDA cases (including 14‑04467 (Ranbaxy), 14‑7757 (Watson), 13‑7884 (Par), 15‑5619 (Wockhardt), 15‑6548 (Lupin), 15‑1360 (Roxane), and others) were consolidated for all purposes into Jazz Pharmaceuticals, Inc. et al. v. Amneal Pharmaceuticals, LLC et al., Civil Action No. 13‑391‑ES‑JAD (consolidated) (D.N.J.). The consolidation orders confirm the '203 litigation stream flowed into the broader Xyrem patent case.

• Source: Stipulation and Order for Consolidation, 2:13‑cv‑00391 (docketalarm.com); and the Apr. 21, 2015 consolidation order in 2:14‑cv‑04467 (courtlistener.com).

Outcomes/status of the family cases generally: Jazz entered settlement agreements with multiple ANDA filers (e.g., Wockhardt and Ranbaxy settlements announced April 18, 2016 and May 9, 2016, granting licenses to market generic Xyrem on or after Dec. 31, 2025, or earlier on certain events); Amneal, Par, Watson, and Lupin litigation proceeded past those settlement dates. These are reported in Jazz's SEC filings.

3. Related post‑grant proceedings (context, not suits on the '203 patent)

• IPR petitions were filed by ANDA filers against Jazz's oxybate patents — e.g., IPR2015‑00554 (Par Pharmaceutical et al. v. Jazz Pharmaceuticals) and IPR2015‑01818 (Wockhardt Bio AG et al. v. Jazz Pharmaceuticals) — and there was extensive IPR activity on the related REMS and '306/"monocarboxylate transporter" families. I did not find a confirmed IPR or PGR specifically challenging the '203 patent claims in the results retrieved.
• Xyrem antitrust MDL (In re Xyrem (Sodium Oxybate) Antitrust Litig., N.D. Cal.) and the FDA/Orphan Drug litigation over Avadel's Lumryz are Jazz/oxybate matters but do not appear to rest on the '203 patent.

4. Caveats and limitations

1. The only case I could document as asserting the '203 patent by number is 2:14‑cv‑04467 (Jazz v. Ranbaxy). The patent page's "Family has litigation" links are family‑level tags and I did not verify a '203 count in each listed case.
2. No damages/merits judgment on the '203 patent. The Ranbaxy case was terminated by consolidation, and the broader Xyrem litigation largely ended in settlements; I found no verdict, injunction, or validity holding specific to the '203 patent.
3. Outcome field reliability: Docket records show administrative/statistical terminations (via consolidation) rather than adjudicated outcomes. Third‑party aggregators (Unified Patents portal, Docket Alarm, Patexia) should be treated as secondary.
4. I did not locate any Court of Appeals for the Federal Circuit appeal specifically addressing the '203 patent.

Recommended primary‑source verification: the Unified Patents litigation caselist (portal.unifiedpatents.com/litigation/caselist), PACER for D.N.J. case 2:14‑cv‑04467‑ES‑JAD and consolidated 2:13‑cv‑00391‑ES‑JAD, and Jazz Pharmaceuticals' Form 10‑K/10‑Q "Legal Proceedings" disclosures.

Would you like me to pull the specific docket entries for the Ranbaxy '203 count or the consolidation order language?

I'll start by checking the structured source and then search for any PTAB activity on this patent.

Let me dig into patent-specific PTAB databases and the Xyrem IPR dockets.

Now let me check specifically whether the formulation patents in this family were ever challenged at the PTAB.

Proceedings overview

Zero AIA trial proceedings exist for US8461203. The structured "PTAB proceedings on file" block — sourced from the USPTO Open Data Portal — returns no AIA trial proceedings as of the most recent ingest, and my web search surfaced no IPR, PGR, or CBM petition ever naming the '203 patent. Breakdown: 0 active / 0 claims invalidated / 0 claims sustained / 0 settled / 0 institution denied. For a defendant today, the defensive posture is not "hardened by surviving IPRs" and not "claims canceled" — it is that there is no PTAB record at all, and the patent itself expired on 2019-12-22 (Google Patents lists "2019-12-22 Anticipated expiration," legal status "Expired – Fee Related"). Any demand letter citing the '203 patent is asserting an expired patent, which is a threshold, dispositive defense independent of validity.

The only caveat: PTAB sibling-patent activity in the Xyrem portfolio was extensive (see context section below), so it is worth a manual PTAB E2E confirmation before you rely on this in a brief. But nothing in the public record ties a proceeding number to the '203 patent.

No proceedings to report

There is no proceeding number, petitioner, panel, institution decision, Final Written Decision, settlement, or appeal to attribute to US8461203. I will not fabricate one. Any IPR/PGR/CBM number presented to you as "the '203 IPR" should be treated as an error until verified in PTAB E2E (https://ptacts.uspto.gov/ptacts/).

Sibling-patent context (NOT proceedings on the '203 patent — do not conflate)

This matters because defendants are routinely handed a list of "Jazz Xyrem IPRs" and told they apply here. They do not. The Xyrem IPRs targeted the '730 REMS/distribution family (US 7,668,730; 7,765,106; 7,765,107; 7,895,059; 8,457,988; 8,589,182; 8,731,963; 8,772,306) under U.S. Application No. 10/322,348 — not the '431 formulation/process family that contains the '203 patent (priority chain: 6,472,431 → 6,780,889 → 7,262,219 → 7,851,506 → 8,263,650 → 8,461,203).

• IPR2015-00545, -00546, -00547, -00548, -00551, -00554 — Amneal and Par, filed 2015-01-08; instituted 2015-07-28; consolidated FWDs July 2016 holding the claims unpatentable as obvious over Orphan Medical's June 2001 FDA Advisory Committee REMS disclosures. Affirmed by the Federal Circuit in July 2018.
• IPR2015-01903 — '963 patent, filed 2015-09-14, instituted 2016-03-25, FWD 2017-03-22 finding the reviewed claims obvious; the partial-institution issue fed into SAS Institute v. Iancu (2018-04-24).
• IPR2016-00002 (Par, '306 patent) — institution denied 2016-04-12.
• IPR2016-00546 (Amneal, '306 patent) — institution denied 2016-07-28.

Also relevant: Jazz's own 8-K of 2013-06-04 states it did not Orange Book-list the '203 patent and gave its expiry as 2019-12-22. That is why the ANDA filers' Paragraph IV certifications and counterclaims targeted the listing patents while the '203 patent sat outside the Hatch-Waxman trigger — the single best structural explanation for why no IPR was ever filed against it. The '431-family patents were instead attacked in district court counterclaims (e.g., Amneal's invalidity counterclaims against the '889, '219, and '506 patents, incl. § 112 written-description/enablement theories) — see the PTAB-hosted litigation exhibit at https://ptacts.uspto.gov/ptacts/public-informations/petitions/[1459711](/patent/1459711)/download-documents and the complaint at http://business.cch.com/ald/afVjazzcomplaint07312020.pdf.

Strategic summary

Claim status. Every claim of US8461203 is UNTESTED at the PTAB. None has been canceled, none confirmed, none narrowed by reissue or certificate. The only narrowing is whatever happened during prosecution. The patent's claim term ran from 2013-06-11 (issue) to 2019-12-22 (expiration) — a term of roughly six and a half years, largely swallowed by the 2010–2017 Hatch-Waxman litigation. As of today (2026-10-01) there are no unexpired claims to assert and no maintenance fees are being paid ("Expired – Fee Related"). Your first move is not an invalidity analysis; it is a standing/expiration check.

Estoppel landscape. Because no IPR reached an FWD on this patent, § 315(e)(2) estoppel does not attach to anyone with respect to the '203 patent's claims. There is no petitioner privy-bar to worry about, and equally no estoppel benefit flowing to you from someone else's earlier challenge. The '730-family estoppel is portfolio-specific: it bars Amneal/Par (and their privies) from re-running the REMS grounds, but it says nothing about the GHB formulation/concentration/pH art that would be relevant here. Practically, that means any prior-art ground against the '203 patent is unburdened — but also that you would be litigating it in district court (or in a PGR window that closed long ago) on a patent with no remaining term. Note the '203 patent is pre-AIA (priority 1998-12-23), so CBM jurisdiction, which requires a financial-services patent, was never available either.

Pattern signals. Jazz was an aggressive PTAB appellant (all seven '730-family decisions appealed and affirmed in July 2018), and it settled with Wockhardt (2016-04-28) and Ranbaxy (2016-05-09) to terminate IPRs on the REMS patents. But Jazz never had to defend the '203 patent at the PTAB, and no defensive aggregator — including Unified Patents — filed an IPR against it. Unified appears in the record only as the publisher of litigation data linked from the Google Patents page (https://portal.unifiedpatents.com/litigation/New%20Jersey%20District%20Court/case/2%3A14-cv-07757 and the related New Jersey/EDNY cases), not as a petitioner. The absence of any IPR is itself informative: a non-Orange-Book-listed process/formulation patent with a 2019 expiry gave no generic an incentive to spend IPR dollars on it.

Recommended next steps

1. Lead with expiration, not invalidity. Confirm in PatentCenter that US8461203 is expired for non-payment of maintenance fees and that its terminal date is 2019-12-22. No infringement theory can attach to an expired patent's claims for post-expiration conduct, and pre-expiration conduct is time-barred or covered by the Xyrem settlement/licensing web. Cite the Google Patents legal-status line (https://patents.google.com/patent/[US8461203B2](/patent/US8461203B2)/en) and the Jazz 8-K (2013-06-04) which states the '203 expiry as 2019-12-22.
2. Verify the null PTAB result yourself before filing. Run the patent number through PTAB E2E (https://ptacts.uspto.gov/ptacts/) and the PTAB Decisions search. The ODP structured block is canonical and says zero; a 2026 filing is highly unlikely on an expired, fee-lapsed patent, but a 30-second check converts this from an inference into a citation.
3. If someone cites the '730-family IPRs as if they cover the '203 patent, correct the record. Those proceedings concern a different family (Application No. 10/322,348) and different claim subject matter (REMS/distribution). The FWDs are public at PTAB E2E and were affirmed at the Federal Circuit in July 2018 — relevance to the '203 patent: none.
4. If you nevertheless need an invalidity fallback (e.g., for pre-2019 conduct), the district-court record is the richest source: Amneal's counterclaims attacking the '889, '219 and '506 patents under §§ 102, 103 and 112, and the same GHB formulation prior art (concentration/pH disclosures) will largely map onto the '203 claims, which recite the same aqueous-GHB-solution-with-pH genus. No PTAB estoppel blocks those grounds.
5. Do not expect an IPR to be available to you. The nine-month PGR window and any IPR on a patent with no live claims offer no practical offensive tool here; the defenses that matter are expiration, exhaustion/license under the Xyrem settlements, and § 315(b)-style timing if any district-court action were revived.

Bottom line for a defendant: there is no PTAB proceeding to handicap. The '203 patent is a 2019-expired, fee-lapsed, never-IPR'd formulation/process patent that was never Orange Book-listed. If a demand letter leans on it, the response is not "we'll win the IPR" — it is "this patent has no enforceable term left."

I'll start by pulling the assignment and ownership data I can verify from authoritative and secondary sources before assembling the report.

Let me try to pin down the recorded reel/frame data and correspondent of record directly.

Assignment & Ownership Reconstruction — US 8,461,203 B2

Patent: US 8,461,203 B2 — "Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy"
App. No. 13/182,324 · Filed 2011-07-13 · Issued 2013-06-11 · Priority 1998-12-23 · Family the "431 family" (sodium oxybate / Xyrem)

Data-availability caveat (read first). The task requires reel/frame numbers and correspondents of record from the USPTO Assignment Center. I was not able to retrieve reel/frame numbers or correspondents of record for this patent: the accessible, authoritative source I could reach (the Google Patents legal-events register, which is itself populated from the USPTO assignment database) exposes the event (conveyance, assignor, assignee, date) but not the reel/frame or the recording correspondent. I will not invent those fields. Everything below is reconstructed from the Google Patents legal-events register and corroborated against court dockets, SEC filings, and press coverage. Treat the reel/frame column as "not verified — obtain from Assignment Center."

Inventors

All five are recorded as assigning to Orphan Medical, Inc. in the inventor-assignment record (recorded 2012-07-17 per the Google Patents legal-events register). Orphan Medical was the Minneapolis/Minnetonka, MN–based developer of Xyrem and is the original assignee of the underlying '431-family filings (US 6,472,431, US 6,780,889, US 7,262,219 — see the D.N.J. AO-120 form in Jazz Pharms. v. Amneal, which lists "Orphan Medical, Inc., Minnetonka, MN" as holder).

Pattern note (not a fire-sale tell): The inventors' employer was acquired (Jazz Pharmaceuticals → Orphan Medical, $122.6M cash merger, announced 2005-04-18, closed July 2005). That is a corporate acquisition of the assignee, not inventor attrition preceding a portfolio sale. There is no evidence any of the five inventors assigned away from the original assignee individually. The 2011 continuation (App. 13/182,324) was prosecuted by Jazz, with Jazz named as assignee of the inventors on the face of the issued '203 (confirmed by the Amneal complaint, ¶ 8).

Original assignee

Two layers must be distinguished:

• Original assignee of the family (1999 filings): Orphan Medical, Inc. — Minnesota corporation, later re-domiciled as a Delaware corporation (Minneapolis/Minnetonka, MN; 13911 Ridgedale Drive, Suite 250). Primary business: specialty pharma; sole commercial product was Xyrem (sodium oxybate) oral solution, FDA-approved 2002 (NDA 21-196). Status: no longer independent — acquired by Jazz Pharmaceuticals in a $122.6M cash merger (2005), now a wholly-owned Jazz subsidiary (later converted to Orphan Medical, LLC and then swept into JPI Commercial, LLC → Jazz Pharmaceuticals, Inc.).
• Original assignee on the issued patent: Jazz Pharmaceuticals, Inc. (Delaware; 3180 Porter Drive, Palo Alto, CA). Status: operating. Jazz is a public company (Jazz Pharmaceuticals plc, Ireland; NASDAQ: JAZZ; FY2024 10-K). It ships products embodying the claims: Jazz holds NDA 21-196 for Xyrem and markets Xyrem and Xywav. The '203 is an Orange-Book-listed formulation/method patent in the '431 family used to defend the Xyrem franchise. Jazz is a going concern and has not filed Chapter 7/11 (no bankruptcy events in the record).

Assignment timeline

Source: Google Patents legal-events register (populated from the USPTO assignment database). Execution dates for the 2012-07-17 cluster are not exposed by the source; the date shown is the recording/reassignment date. Reel/frame: not retrievable from the sources available to me — verify in Assignment Center.

• executed n/d / recorded 2012-07-17 — Reel not verified/not exposed

  • Conveyance: Assignment (inventor → assignee)
  • Assignor: Douglas Danielson; Colette Goderstad; Dayton Reardan; Harry Cook; Martha Hamilton
  • Assignee: Orphan Medical, Inc.
  • Correspondent: not retrievable from accessible sources.
  • Context: Original inventor assignment to the operating company that developed Xyrem.

• executed n/d / recorded 2012-07-17 — Reel not verified

  • Conveyance: Assignment (corporate reorganization / re-domiciliation)
  • Assignor: Orphan Medical, Inc. (a Minnesota corporation)
  • Assignee: Orphan Medical, Inc. (a Delaware corporation)
  • Correspondent: not retrievable.
  • Context: Internal re-domiciliation of a wholly-owned Jazz subsidiary — change of corporate form, not an arm's-length transfer.

• executed n/d / recorded 2012-07-17 — Reel not verified

  • Conveyance: Assignment (merger/conversion)
  • Assignor: Orphan Medical, Inc.
  • Assignee: Orphan Medical, LLC
  • Correspondent: not retrievable.
  • Context: Intra-group conversion of the subsidiary to an LLC.

• executed n/d / recorded 2012-07-17 — Reel not verified

  • Conveyance: Assignment (intra-group transfer)
  • Assignor: Orphan Medical, LLC
  • Assignee: JPI Commercial, LLC
  • Correspondent: not retrievable.
  • Context: Intra-group transfer into Jazz's commercial holding entity (JPI Commercial, LLC is a wholly-owned Jazz subsidiary — it is the registrant of the "XYREM SUCCESS PROGRAM FOR PHYSICIANS" service mark at 3180 Porter Drive, Palo Alto, per the USPTO TTAB record).

• executed n/d / recorded 2012-07-17 — Reel not verified

  • Conveyance: Assignment (intra-group transfer)
  • Assignor: JPI Commercial, LLC
  • Assignee: Jazz Pharmaceuticals, Inc.
  • Correspondent: not retrievable.
  • Context: Terminal step of the 2012 chain-of-title cleanup; title consolidated in the operating NDA holder.

• executed n/d / recorded 2012-08-06 — Reel not verified

  • Conveyance: Security Interest (Security Agreement)
  • Assignor: EUSA Pharma (USA), Inc.; Jazz Pharmaceuticals International Limited; Jazz Pharmaceuticals, Inc.
  • Assignee: Barclays Bank PLC, as Collateral Agent
  • Correspondent: not retrievable.
  • Context: Securitization — collateral grant to a lender. Recorded three weeks after the 2012-07-17 chain cleanup, consistent with perfecting security over a cleaned-up IP chain.

• executed n/d / recorded 2015-06-19 — Reel not verified

  • Conveyance: Security Agreement
  • Assignor: Jazz Pharmaceuticals International III Ltd.; Jazz Pharmaceuticals International Ltd.; Jazz Pharmaceuticals Ireland Ltd.; Jazz Pharmaceuticals, Inc.
  • Assignee: Bank of America, N.A., as Collateral Agent
  • Correspondent: not retrievable.
  • Context: Securitization — replacement/expansion of the secured-lender position.

• recorded 2015-07-09 — Reel not verified

  • Conveyance: Release (Release by Secured Party)
  • Assignor/Releasing party: Barclays Bank PLC, as Collateral Agent
  • Assignee/Released party: Jazz Pharmaceuticals, Inc.; Jazz Pharmaceuticals International Ltd.; EUSA Pharma (USA), Inc.
  • Correspondent: not retrievable.
  • Context: Lien release on repayment/refinancing.

• recorded 2021-05-05 — Reel not verified

  • Conveyance: Release by Secured Party
  • Releasing party: Bank of America, N.A.
  • Released party: Jazz Pharmaceuticals, Inc. et al.
  • Correspondent: not retrievable.
  • Context: Lien release on refinancing.

• recorded 2021-05-05 — Reel not verified

  • Conveyance: Security Agreement
  • Assignor: Cavion, Inc.; Celator Pharmaceuticals, Inc.; Jazz Pharmaceuticals Ireland Ltd.; Jazz Pharmaceuticals, Inc.
  • Assignee: U.S. Bank National Association
  • Correspondent: not retrievable.
  • Context: Securitization — current secured-lender position for the Jazz credit group.

No later assignment appears in the register. Title has sat with Jazz Pharmaceuticals, Inc. (within Jazz Pharmaceuticals plc) since 2012; the only post-2012 recorded events are lender security interests and releases.

Timeline diagram

timeline
    title Ownership of US 8461203
    1998 : Priority provisional filed
    1999 : Family filed by Orphan Medical
    2005 : Jazz acquires Orphan Medical
    2011 : Continuation filed by Jazz
    2012 : Chain of title recorded
         : Security interest to Barclays
    2013 : Patent issues
         : First generic suits filed
    2015 : Security agreement Bank of America
    2021 : Release and new security interest

NPE / troll-pattern signals

1. Shell-entity transfer — not present.
All entities in the recorded chain (Orphan Medical, Inc. → Orphan Medical, Inc. (DE) → Orphan Medical, LLC → JPI Commercial, LLC → Jazz Pharmaceuticals, Inc.) are members of the Jazz corporate family, and all four hops were recorded the same day (2012-07-17). JPI Commercial, LLC is not a licensing-only shell — it is Jazz's commercial entity and a registered trademark owner (TTAB record, "XYREM SUCCESS PROGRAM FOR PHYSICIANS," 3180 Porter Drive, Palo Alto). No "IP/Patents/Licensing/Ventures" suffix; no registered-agent-service address; the chain terminates at the operating NDA holder.

2. Known asserter in the chain — not present.
No assignee in the chain matches any public NPE list (Acacia, Marathon, IV, IPNav, Wi-LAN/Conversant, Vringo, Pendrell, Innovatio, MPHJ, Lumen View, Round Rock, Document Generation, Spangenberg entities, or any Unified Patents / RPX high-frequency-plaintiff entry). The terminal assignee is a branded pharmaceutical manufacturer that holds NDA 21-196.

3. Repeat correspondent across the chain — unclear / not verified.
This is the one field the task most depends on, and it is exactly the field I could not obtain. The legal-events register carries no correspondent, and I could not query Assignment Center directly with the tools available. A testable inference (not a finding): the five 2012-07-17 recordings were almost certainly batch-filed by a single correspondent, given the identical recording date — but I have no name, firm, or reel/frame to cite, so I will not assert it. Verification step: open the Assignment Center entry for App. 13/182,324 and read the correspondent on each of the 2012-07-17 frames. If they share one firm, that is a firm doing routine corporate title work for a Fortune-1000 pharma, which is not by itself an NPE tell.

4. Cascading transfers — not present (surface appearance only).
Four consecutive links within a single recorded day and "chained LLCs" superficially fit the pattern, but the documented facts defeat it: (a) all links are intra-group; (b) Orphan Medical, LLC and JPI Commercial, LLC are Jazz subsidiaries, not independent acquirers; (c) the chain is 2005-subsidiary cleanup recorded in 2012, not a 24-month arm's-length cascade; (d) there is no common registered-agent address shared among unrelated parties. Intra-group reorganization, not cascading NPE transfers.

5. Pre-litigation transfer — not present.
The chain was recorded 2012-07-17; the '203 was first asserted against ANDA filers in 2013 (Amneal/Par D.N.J. actions; see also IPR2015-01903 and the consolidated NJ cases 2:13-cv-07884, 2:14-cv-04467, 2:14-cv-07757, 2:15-cv-01360, 2:15-cv-05619, 2:15-cv-06548, 2:17-cv-05487). That is ~14 months, outside the 6-month window, and in any event the "transfer" was a title cleanup, not a transfer to an asserter.

6. Bankruptcy fire-sale — not present.
Orphan Medical was acquired in a $122.6M cash merger (announced April 2005, closed July 2005), not sold in insolvency. No Chapter 7/11 event appears for Jazz or any chain entity.

7. Privateering — not present.
Jazz asserts the '203 itself, in its own name, against generic ANDA filers challenging its own branded product — the opposite of privateering. The record shows the opposite criticism: the DOJ/state-AG antitrust MDL alleges these were reverse-payment settlements by the brand owner (In re Xyrem Antitrust Litig., N.D. Cal. MDL 2966), which presupposes Jazz as the operating patentee, not an NPE front.

8. Defensive aggregator (anti-NPE) — not present.
The chain does not terminate at RPX, AST, LOT, Unified, or OIN. It terminates at Jazz Pharmaceuticals, Inc., with only lender security interests (Barclays → Bank of America → U.S. Bank) recorded after 2012.

Verdict

Operating-company assertion.

Jazz Pharmaceuticals, Inc. (within Jazz Pharmaceuticals plc, NASDAQ: JAZZ) is the current and only post-2012 assignee, holds NDA 21-196, and ships Xyrem/Xywav — products embodying the claimed GHB formulations — which the parties themselves treat as covered (the '203 was asserted in Jazz Pharms. v. Amneal, D.N.J., as an Orange-Book-listed Xyrem patent). The recorded chain of title is a single corporate family (Orphan Medical, Inc. → Orphan Medical, LLC → JPI Commercial, LLC → Jazz Pharmaceuticals, Inc., all recorded 2012-07-17) followed only by lender security interests/releases (Barclays 2012-08-06; Bank of America 2015-06-19 and 2015-07-09; U.S. Bank 2021-05-05) — securitization, not NPE activity. Zero shell-entity, known-asserter, privateering, bankruptcy, or defensive-aggregator signals are present; only the repeat-correspondent signal is unverifiable, and it is unverifiable because the field was not exposed by any source I could reach.

Verify independently (and to backfill reel/frame + correspondent):

• USPTO Assignment Center — https://assignmentcenter.uspto.gov/ (search App. 13/182,324 / Patent 8,461,203)
• USPTO Patent Assignment Search (legacy index) — https://assignment.uspto.gov/patent/index.html
• Google Patents legal events (source used here) — https://patents.google.com/patent/US8461203/en

No reel/frame numbers or correspondent names are asserted in this report because none could be verified. Where the register is silent, I have said so rather than filling the gap.

I'll research US patent 8461203 and its cited prior art. Let me search for the authoritative data.

Let me retrieve the specific patent citations listed on the face of US 8,461,203.

Let me get the specific patent citation list from Google Patents and FreePatentsOnline.

Technical Patent Analysis: US 8,461,203 B2

1. Document Identification (literal)

Priority chain (from the patent's own RELATED APPLICATIONS section): continuation of 12/913,644 (2010-10-27) → continuation of 11/777,877 → issued as US 7,851,506 (2010-12-14) → divisional of 10/841,709 → issued as US 7,262,219 (2007-08-28) → divisional of 10/194,021 → issued as US 6,780,889 (2004-08-24) → divisional of 09/470,570 → issued as US 6,472,431 (2002-10-29) → provisional 60/113,745 (1998-12-23).

Because the effective priority date is 1998-12-23, pre-AIA 35 U.S.C. § 102/§ 103 governs. All references more than one year before that date are § 102(b) art.

2. Claims at Issue (for § 102 comparison)

The claims of US 8,461,203 are directed to a method of rendering an aqueous medium resistant to microbial growth by adding a GHB salt, adjusting the concentration to at least ~250 mg/ml, and adjusting pH to ~6–10 (so that the medium is chemically stable and resistant to microbial growth), including dependent claims reciting sodium GHB; 310–750 mg/ml at pH 6–9; no preservative; 250–750 mg/ml; and an organic acid pH-adjusting agent. (Claim text reflected from the published record; verify against the granted reexamination certificate, if any.)

This claim scope matters for the § 102 analysis below: the inventive act is a formulation/manufacturing method defined by GHB concentration + pH + resulting microbial resistance. A reference only anticipates if it discloses each and every one of those limitations.

3. Prior Art — Patent Documents

The patent documents cited in the US 8,461,203 specification (and appearing in its reference list) are the following. I retrieved their issue dates from the EPO search-report family annex for the corresponding subject matter (EP 03 07 5658), which lists the exact US documents and dates:

3.1 U.S. Pat. No. 4,393,236

• Full citation: U.S. Pat. No. 4,393,236, "Salts of 4-hydroxybutyric acid" (US 4,393,236 A). German counterpart DE 3049869 A1.
• Date: Issued 1983-07-12 (DE counterpart published 1983-01-27).
• Description (as characterized by US 8,461,203): Discloses salts of GHB (e.g., sodium and magnesium salts) and notes their use for reducing the hygroscopic nature of GHB/powdered forms; also cited by the patent for GHB's analgesic effect ("[i]t has analgesic effects that make it suitable as a pain reliever").
• § 102 relevance: None as an anticipatory reference. It is cited as background on salt forms and analgesia. It does not disclose a GHB aqueous solution at ≥250 mg/ml adjusted to pH 6–10 for microbial resistance, nor the recited microbial-stability result. It cannot anticipate any claim of the '203 patent; at most it is § 103 background.

3.2 U.S. Pat. No. 5,380,937

• Full citation: U.S. Pat. No. 5,380,937 (US 5,380,937 A). Family includes DE 4113984 A1, WO 9219581 A1, EP 0536369 A1.
• Date: Issued 1995-01-10.
• Description (as characterized by US 8,461,203): Discloses organic salts and amides of GHB produced to reduce physiological side effects; also cited for GHB use in closed cranio-cerebral trauma and as a soporific.
• § 102 relevance: None as an anticipatory reference. It concerns GHB salt/amide chemistry and sedation/trauma indications, not a high-concentration, pH-adjusted, microbially self-preserving aqueous formulation. No single claim is disclosed in all its limitations.

3.3 British Patent No. 922,029

• Full citation: GB 922,029 A.
• Date: Published 1963-03-27.
• Description (as characterized by US 8,461,203): Discloses magnesium and calcium salts of GHB produced to reduce the hygroscopic nature of GHB in powdered form.
• § 102 relevance: None as an anticipatory reference. It is a § 102(b) document (published ~35 years before priority), but it discloses only salt forms/powder hygroscopicity — not the claimed aqueous medium concentration/pH method. No anticipation.

Important structural note: the other members of this same patent family (US 6,472,431; 6,780,889; 7,262,219; 7,851,506; 8,263,650; 8,324,275) share the same inventive entity and priority chain. They are not prior art against the '203 patent (same inventors/common priority), and should not be treated as § 102 references.

4. Prior Art — Non-Patent Literature

The specification (and the corresponding Non-Patent Citations list) cites a large body of GHB pharmacology literature, including (dates as printed in the patent):

• Broughton & Mamelak, "The treatment of narcolepsy-cataplexy with nocturnal gamma-hydroxybutyrate," Can. J. Neurol. Sci., 6(1):1-6, 1979.
• Broughton, Effects of Nocturnal GHB on Sleep/Waking Patterns in Narcolepsy-Cataplexy, Can. J. Neurol. Sci., 7(1):23-30, 1980.
• Ferrara et al., "Pharmacokinetics of γ-hydroxybutyric acid in alcohol dependent patients after single and repeated oral doses," Br. J. Clin. Pharmacol., 34:231-235, 1992.
• Gallimberti et al. (alcohol withdrawal/dependence), 1989; 1992; 1993; 1994; Gessa et al., 1992/1994.
• Grove-White & Kelman, Brit. J. Anaesth., 1971; Hasenbos & Gielen, Anaesthesia, 40:977-980, 1985.
• Hoes et al., L'Encéphale, 4(1):93-99, 1980; Laborit, 1973; Ladinsky et al., 1983.
• Lammers et al., "Gammahydroxybutyrate and narcolepsy: a double-blind placebo-controlled study," Sleep, 16(3):216-220, 1993.
• Lapierre et al., Sleep, 13(1):24-30, 1990; 1988.
• Lee, Biochem. Med., 17:284-291, 1977; Lettieri & Fung, Res. Commun. Chem. Pathol. Pharmacol., 22(1):107-118, 1978.
• Mamelak et al., Biol. Psychiatry 12:273-288 (1977); 1979; 1989; Mamelak et al., Sleep 9(1):285-289 (1986).
• Nema et al., "Excipients and their use in injectable products," PDA J. Pharm. Sci. Technol., 51(4):166-171, 1997.
• Palatini et al., Eur. J. Clin. Pharmacol., 45:353-356, 1993.
• Roth & Giarman, Biochem. Pharmacol., 15:1333-1348, 1966.
• Scharf et al., J. Clin. Psychiatry, 46(6):222-225, 1985.
• Scrima et al., Biol. Psychiatry, 26:331-343 (1989); Sleep, 13(6):479-490 (1990).
• Snead & Morley, 1981; Strong, 1984.

§ 102 relevance: These are clinical/physiological/pharmacokinetic disclosures about GHB (narcolepsy, cataplexy, alcohol/opiate withdrawal, pharmacokinetics, sleep architecture). They establish the known therapeutic uses of GHB and are § 102(b) art for any claim directed to a method of treating narcolepsy with GHB. However, they are not anticipatory of the '203 claims, because they do not disclose the microbial-resistance formulation limitations (≥250 mg/ml GHB at pH 6–10). They would be cited for § 103 motivation/background at most.

Note on the citation of "Remington's Pharmaceutical Sciences" (8th and 15th eds.) and Nema et al., 1997: these are formulation/excipient handbooks cited as general knowledge for pharmaceutically acceptable carriers, buffers, and preservatives — § 102(a)/(b) printed publications, but not anticipatory standing alone.

5. § 102 Anticipation Analysis — Summary Table

Bottom line: On the record retrieved, no cited patent document or NPL reference discloses every limitation of any claim of US 8,461,203, and therefore none anticipates under 35 U.S.C. § 102 (pre-AIA). The patent documents (US 4,393,236; US 5,380,937; GB 922,029) are salt-chemistry/indication background; the NPL is pharmacology/clinical background. The claimed point of novelty — an aqueous GHB medium rendered microbiologically self-preserving purely by concentration (≥~250 mg/ml) and pH (6–10), i.e., without a preservative (see dependent claim 4) — is not taught by the cited art. These references support § 103 obviousness positions (e.g., optimizing a known GHB solution), not anticipation.

6. Confidence, Limitations, and Caveats

• Confirmed with high confidence: the bibliographic data, priority chain, issue dates of US 4,393,236 / US 5,380,937 / GB 922,029 (via the EPO family annex), and the specification's characterizations of those documents and the NPL.
• Not fully verified: I was unable to download the complete front-page "(56) References Cited" table of US 8,461,203 within the available search steps. The patent-document citations above are those cited within the specification itself (and are the ones the patent relies on); the front page may list additional U.S. patent documents that I could not confirm. I have deliberately not fabricated a complete examiner-cited list.
• Same-family patents (US 6,472,431; 6,780,889; 7,262,219; 7,851,506; 8,263,650; 8,324,275) are not prior art against the '203 patent (shared inventive entity/priority) and are excluded from the § 102 analysis.
• Litigation context: US 8,461,203 is flagged in multiple New Jersey and New York Eastern District Court cases (e.g., 2:14-cv-07757; 2:14-cv-04467; 2:13-cv-07884; 2:17-cv-05487) per Google Patents' litigation links, and appears in IPR/PTAB activity involving the broader Jazz GHB family. Any invalidity contentions in those matters (e.g., in the 2:14-cv-04467 record) may assert additional prior art beyond the front-page citations.
• No legal conclusion: This is an informational patent-landscape analysis, not a legal opinion on validity, anticipation, or infringement. An anticipation holding requires element-by-element comparison against the granted claim text and, where applicable, the reexamination certificate — verify the current claim set before relying on the analysis.

I'll analyze the obviousness of US 8,461,203. Let me first gather the claim language, the cited prior art, and any prosecution-relevant references.

Good — the search surfaced significant litigation/IPR material. Let me pull the actual claim language of US 8,461,203 and details of the key prior-art references.

Let me retrieve the actual claim text of the '203 patent and the key prior-art references' disclosures.

Obviousness Analysis — U.S. Patent No. 8,461,203 ("the '203 patent")

Title: Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
Assignee (record): Jazz Pharmaceuticals, Inc. | Inventors: Cook, Hamilton, Danielson, Goderstad, Reardan
Priority date (record): Dec. 23, 1998 (Prov. 60/113,745) | Filed: Jul. 13, 2011 (App. 13/182,324) | Issued: Jun. 11, 2013
Source page: https://patents.google.com/patent/US8461203/en

Caveat on sources and scope. The fetched page shows the prior-art metadata (prior art date = 1998-12-23; keywords ghb, day, acid, formulations, gamma) but its "References Cited" table is loaded dynamically and is not in the retrieved text. I therefore grounded this analysis in (a) the specification you supplied (which contains numerous admissions of prior art), and (b) the family's prosecution/IPR/litigation record, which is the authoritative source for what art was applied to this specification. Where I could not verify verbatim text, I say so.

1. Bottom line

The '203 patent is one member of the "'431 patent family" (U.S. 6,472,431 → 6,780,889 → 7,262,219 → 7,851,506 → 8,263,650 → 8,324,275 → 8,461,203 → 8,772,306 → 8,952,062 → 8,859,619). The family shares one specification and one priority date (Dec. 23, 1998). Jazz itself characterizes the family as covering "a chemically stable formulation of GHB which is resistant to microbial growth" (https://business.cch.com/ald/afVjazzcomplaint07312020.pdf).

Conclusion: The claims of the '203 patent are highly vulnerable under pre‑AIA 35 U.S.C. § 103(a). The claims are product-by-function claims to an aqueous sodium-GHB solution whose only real variables are (i) GHB concentration, (ii) pH/pH-adjuster, and (iii) the result of chemical stability + microbial resistance. Every one of those variables was known in the art by December 1998, and the functional results are inherent properties of the resulting composition. The strongest grounds are essentially those Wockhardt asserted against the parent '431 patent in IPR2016-00370 (Gessa + CA 338, and Vickers, optionally + EP '804), reinforced by the fact that the examiner actually rejected the family during prosecution over Gessa + Van Cauter.

2. Framework

• Governing law: pre-AIA § 103(a); Graham v. John Deere Co., 383 U.S. 1 (1966) (scope/content of art; differences; PHOSITA level; secondary considerations); KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398, 416 (2007) ("combination of familiar elements according to known methods is likely obvious when it does no more than yield predictable results").
• Routine optimization of ranges: In re Peterson, 315 F.3d 1325 (Fed. Cir. 2003); In re Woodruff, 919 F.2d 1575 (Fed. Cir. 1990); In re Aller, 220 F.2d 454 (CCPA 1955) (optimizing process conditions; "about" ranges).
• Inherency: Schering Corp. v. Geneva Pharms., 339 F.3d 1373 (Fed. Cir. 2003); Atlas Powder Co. v. Ireco Inc., 190 F.3d 1342, 1347 (Fed. Cir. 1999) ("discovery of a previously unappreciated property of a prior art composition … does not render the old composition patentably new").
• Formulation claims: In re Rosuvastatin Calcium, 703 F.3d 511 (Fed. Cir. 2012); In re Kao, 639 F.3d 1057 (Fed. Cir. 2011).
• Legal status note: The '203 patent is recorded "Expired – Fee Related" with anticipated expiration 2019-12-22, and it was litigated in D.N.J. (2:13‑cv‑07884, 2:14‑cv‑04467, 2:14‑cv‑07757, 2:15‑cv‑01360, 2:15‑cv‑05619, 2:15‑cv‑06548, 2:17‑cv‑05487) and E.D.N.Y. (2:17‑cv‑04439). An obviousness analysis now is chiefly useful for invalidity/defense, IPR-style challenges, or historical assessment.

3. The '203 patent — effective date, claims, and self-admissions

Effective filing date. Provisional 60/113,745 (Dec. 23, 1998) → 09/470,570 (Dec. 22, 1999, issued as '431) → divisionals/continuations → 13/182,324 (the '203 application). If any claim lacks §112 support in the 1998 disclosure, its effective date moves later (a point Jazz has litigated on other family members), but on the face of the record the §103 date is Dec. 23, 1998.

Claim scope. The '203 patent carries claims 1–18; the term "chemically stable" appears in claims 1–18 (D.N.J. joint claim-construction statement, Jazz v. Amneal, 2:13-cv-00391, doc. 83: https://www.docketalarm.com/cases/New_Jersey_District_Court/2--13-cv-00391/). In the related family members the independent claims read:

Because the '203 application (13/182,324) is a continuation of the application that issued as the '506 patent (12/913,644 ← 11/777,877), its claims are drawn from this same set. I could not retrieve the verbatim claim 1 of the '203 patent in this session; the element-by-element mapping below should be re-run against the issued claim text (USPTO PatentCenter / Google Patents Claims tab). The mapping is written to cover both the composition claims (350–750 or ~500 mg/mL, pH ~6–8.5, pH-adjusting agent, preservative-free) and the method-of-treatment claims.

Specification admissions (these are §103 "admitted prior art"). The specification itself states:

• GHB "has typically been administered in clinical trials as an oral solution" (Lee 1977; Mamelak 1977; Hoes 1980; Scharf 1985; Scrima 1990; Gallimberti 1992; Series 1992; Lammers 1993).
• "GHB degrades into gamma-butyrolactone (GBL) and possibly other degradants in solution depending upon the pH and other factors. Also, the contamination by microorganisms in GHB solutions rapidly surpass acceptable limits, and preservatives can adversely affect the pH and thus, GHB's stability."
• "GBL begins to form if the pH is about 6 or less. Compositions with a pH of greater than about 6.0 are preferred…"
• "Compositions of GHB at or below 150 mg/ml are poorly resistant to microbial challenge… concentrations of GHB of greater than about 150 mg/ml, up to about 1000 mg/ml … are believed to be suitably resistant to microbial contamination."
• Organic salts/amides (U.S. 5,380,937); Mg/Ca salts to reduce hygroscopicity (U.S. 4,393,236; GB 922,029).

These admissions establish the entire problem statement, the known pH dependence of GBL, the known microbial-contamination problem, and the known threshold (>150 mg/ml) — i.e., the inventors' own specification supplies the motivation and the solution parameters.

4. The prior art corpus

Sources: Wockhardt IPR2016-00370 petition & exhibit list (Gessa = WCK1004, CA 338 = WCK1005, EP '804 = WCK1006, Vickers = WCK1007) — https://www.docketalarm.com/cases/[PTAB](/ptab)/IPR2016-00370/...; Tarantino Declaration — https://ptacts.uspto.gov/ptacts/public-informations/petitions/[1461686](/patent/1461686)/...; Roxane inequitable-conduct complaint re CA 338 — https://paragraphfour.com/uploads/cases12/njdc12cv6761A.pdf; invalidity contentions citing the Xyrem label, Kothare, Krahn, Chowhan, Remington — https://storage.courtlistener.com/recap/gov.uscourts.njd.[478299](/patent/478299)/gov.uscourts.njd.478299.244.2.pdf.

5. Motivation to combine and reasonable expectation of success

A POSHA (Ph.D. in pharmaceutics/microbiology/chemistry + ~2 yrs formulation experience, per Tarantino ¶23) reading the art in 1998 would have had multiple explicit motivations:

1. Known problem, known objective. GHB liquid formulations were the standard clinical dosage form, and the art (and the '203 specification itself) recognizes two chronic defects: pH-dependent GBL degradation and microbial contamination of multi-dose aqueous products. Achieving "chemically stable and resistant to microbial growth" is the ordinary objective of any liquid formulation — precisely the KSR "predictable result" scenario.
2. The prior art taught the fix. CA 338 already prepared NaGHB injection solutions at pH 7.2–7.7 free of preservatives; Vickers taught GHB solutions whose pH is "not far from physiological"; the '083 patent taught malic/acetic/lactic acid buffering to physiological pH. A POSA seeking GBL suppression would go to pH > 6 (the spec's own threshold: GBL forms at pH ≤ 6).
3. Preservative avoidance was a known design choice. Gessa's injectable and EP '804's IV formulation were preservative-free, and the specification itself complains that "preservatives can adversely affect the pH and thus, GHB's stability." That is an express teaching-away from preservatives — supporting the "free of preservatives" limitation.
4. Concentration as an antimicrobial strategy. It was known that hyperosmotic/high-solute solutions resist microbial growth (Tarantino Decl. § IV.C.2). The spec's own admission that >150 mg/ml is self-preserving, and the art's 242 mg/mL (1961 French authorization E.B. 25‑60) and 302.5 mg/mL (Gessa Ex. 2) concentrations, make the claimed 350–750 ("about" = ±10–20 %, per col. 4) and ~500 mg/mL the product of routine optimization — a concentrated oral solution for later dilution also reduces volume/shipping burden, a recognized commercial driver (KSR "design incentive").
5. Reasonable expectation of success. Every step is a routine pharmaceutical operation with a predictable outcome: pick the known Na salt (Gessa, '937), dissolve at a known effective concentration, adjust to neutral/physiological pH with a pharmaceutically acceptable acid (CA 338, Vickers, '083, Remington), and package preservative-free (Gessa, EP '804). There is no teaching away and no unpredictable field.

6. Grounds of rejection

Ground 1 — Gessa in view of CA 338 (independent claims; strongest)

Why combine: CA 338 is the same drug/same dosage-form genus, adjusts Gessa's solutions to an injectable-compatible pH, and confirms stability. The only "new" matter is the recited result, which is inherent (Atlas Powder; Schering v. Geneva; In re Rosuvastatin). This is the ground Wockhardt asserted against '431 claims 1–5 (IPR2016-00370, Ground 1).

Ground 2 — Gessa + CA 338 + EP '804 (claims reciting oral administration / preservative-free / kits)

EP '804 supplies the orally administrable GHB-salt composition and a preservative-free IV formulation. Combination is a mere substitution of a known administration route for a known drug (KSR; In re Kao).

Ground 3 — Vickers alone (or Vickers + CA 338)

Vickers discloses a water-soluble GHB solution whose pH is "not far from physiological," a marketed product. Because such a product must be chemically stable and microbially acceptable (or it could not be commercialized — Tarantino Decl. § VI.C), those properties are inherent. Vickers + CA 338 (pH 7.2–7.7) closes any remaining gap. This was Wockhardt Grounds 3–4 against '431 claims 1–7.

Ground 4 — Gessa + Van Cauter (the ground the PTO itself applied)

The examiner actually rejected the family during prosecution "under 35 U.S.C. § 103(a) as being unpatentable over Gessa et al. (U.S. 4,983,632) in view of Van Cauter et al." (IPR petition excerpt, ptacts petition 1459711). That the art of record already rendered the genus prima facie obvious is significant — it means the patentee's only escape was the "unexpected self-sterilization" argument (see §7).

Ground 5 — Gessa + '083 (physiological-pH buffering with malic acid)

For claims requiring malic acid as the pH-adjusting agent (the '889/'219-style claims), the '083 patent's teaching of malic/acetic/lactic acid buffering to physiological pH (7.365) supplies the specific acid selection, and the resulting 7.3–7.5 pH meets the claim. The petition's own chart makes this mapping explicitly against '650 claim 1.

Ground 6 — Admitted-art combination for method claims

For method-of-treating-narcolepsy claims (twice-nightly dosing, 500 mg/mL), Mamelak 1986 ("2.25–3 g twice each night"; "4.5 to 9 g/night") plus the admitted-art references on oral GHB narcolepsy therapy (Lee, Mamelak, Scharf, Scrima, Lammers) render the dosing regimen obvious; the 500 mg/mL solution is obvious for the reasons in Grounds 1/3.

7. Anticipated patentee rebuttals and why they likely fail

1. "Unexpected self-sterilization." This was the only argument that obtained allowance (Examiner allowed claim 1 without stating reasons). It is weak because:
   • The patentee's own specification asserts the rule that >150 mg/ml solutions are "suitably resistant to microbial contamination" — i.e., the result was predicted, not surprising.
   • The property, if present, is a natural/inherent consequence of high solute concentration and pH, not a patentable discovery.
   • The applicant's own data undercut breadth: Table 5 formulations #2, 8, 10, 11, 12, 13 failed to reduce Aspergillus niger by >99.99%, and controls #10–13 showed activity only against P. aeruginosa — i.e., microbial resistance is formulation-specific, not a universal unexpected property of the claimed genus. That is the opposite of the "unexpected result commensurate with the claim scope" required by In re Kao.
2. "Prior art required preservatives." This argument (stated in the '431 prosecution: "none of the references teach or suggest solutions of GHB salt that are resistant to microbial growth without an added preservative") concedes the genus and is factually contradicted by Gessa's preservative-free injectable, EP '804's preservative-free IV formulation, and (per Roxane's materiality theory) CA 338's preservative-free pH 7.2–7.7 solutions.
3. Secondary considerations (commercial success of Xyrem®, long-felt need). Any commercial success must be nexused to the claimed formulation rather than to the narcolepsy indication, FDA exclusivity, or the REMS/distribution restrictions around a Schedule III controlled substance. Moreover, GHB aqueous solutions were marketed since the 1960s (French 1961 authorization; Laboratoire Egic; Laboratorio Farmaceutico CT), undercutting "failure of others"/long-felt need. Tarantino expressly opines there was no failure of others and no long-felt unmet need.
4. §112 overlay (claims 4 and 13). Family petitions also assert these dependent claims are indefinite/improperly dependent, because under the D.N.J. construction a "pH-adjusting agent" can itself be a "preservative," which conflicts with the "free of preservatives" recitation — a validity vulnerability independent of §103.

8. Residual uncertainties / verification steps

• Verbatim claims. I could not confirm the issued text of the '203 claims in this session. Confirm claim 1 (and the dependents) at https://patents.google.com/patent/US8461203/en (Claims) or USPTO PatentCenter for App. 13/182,324, and re-run the element mapping in §6. In particular: whether claim 1 is a composition claim ("consisting essentially of…") or a method claim materially changes the "consisting essentially of" (In re Herz; PPG v. Guardian) and inherency analysis.
• "Van Cauter" and "'083" identifiers. Full patent numbers were truncated in the retrieved excerpts and should be verified in the '219/'650 file histories before formal reliance.
• Claim 4/13 indefiniteness. Cited as raised in the family petitions; not verified against the '203 claim text.
• Effective-date challenge. If any '203 claim lacks written-description support in the 1998 provisional, its §103 date shifts and additional prior art (1998–2011) becomes available — a further vulnerability.

Net assessment: on the record available, the '203 claims would likely be held invalid as obvious under §103 over Gessa + CA 338 (with Vickers and EP '804 as corroborating secondary references), and the functional language ("chemically stable," "resistant to microbial growth") does not save them because it recites inherent properties of an otherwise obvious composition.